Skip to content
52

cetirizin 100 stück

Worth a look

Shows low returns (0.0%), but strong incumbent ratings (4.7★) keeps it on the watch list.

Market size 64Growth 57Conversion 97Competition 20Returns 100Price range 34Avg price 38Brand share 37Review moat 49Quality gap 18

Returns

Incredible0.0%

return rate — above 6% kills the launch gate

Conversion

Incredible15.3%

search→purchase rate — share of searches ending in a sale

Market size

Good€593K

€593K/yr · 368K searches

Growth

Good+30.5%

90-day search growth — must beat 0% to launch

Review moat

Okay1,575.64

avg incumbent reviews — the moat a new listing must climb

Avg price

Okay€10.54

avg listing price — sweet spot $15–$100

Brand share

Okay83%

top-5 brand share — brands hold most of the demand

Price range

Okay€4.63–€20.46

cheapest to priciest tracked listing — scored on the share inside $15–$100

Competition

Bad75%

top-5 click share — a locked-up shelf

Quality gap

Bad4.7★

avg incumbent rating — lower means beatable quality

Competition

The top 5 products capture 75% of clicks — a locked-up shelf that new listings rarely crack.

Brands

12 rising

Sellers

25

Top-5 brand share

83%

Open market

14%

  • ADGC29%
  • AbZ Pharma20%
  • apo-discounter.de17%
  • Hexal10%
  • AL Aliud Pharma8%
  • STADA3%
  • Open — no brand owns it (6 brands, 14%)

Product shelf

Each bubble is one product — market share against review moat; bubble size tracks estimated sales, color grades how beatable the incumbent looks.

0%10%€59K20%€119K30%€178K40%€237K101001K10K Reviews — right = deep review moat Market share (90d) ≈ est. sales
Beatable (≤4.3★) Contested Strong incumbent (>4.7★)

All 14 tracked products in this niche — three views at once, no toggling.

Demand & seasonality

Weekly Amazon search volume, last 104 weeks — +30.5% search growth over the last 90 days.
15K10KSpike '25Spike '26SepDecMarJunAugNovMarMay

Peak months: Mar, Apr, May, Jun · busiest ÷ quietest = 3.4×